| Literature DB >> 30134863 |
Youngchul Kim1, Christine M Pierce2,3,4, Lary A Robinson3,4.
Abstract
BACKGROUND: In our recent study, most non-small-lung cancer (NSCLC) tumor specimens harbored viral DNA but it was absent in non-neoplastic lung. However, their targets and roles in the tumor cells remain poorly understood. We analyzed gene expression microarrays to identify genes and pathways differentially altered between virus-infected and uninfected NSCLC tumors.Entities:
Keywords: Carcinogenesis; Gene expression; HPV; Human papilloma virus; Non-small cell lung cancer; Retrovirus; Virus
Mesh:
Substances:
Year: 2018 PMID: 30134863 PMCID: PMC6106745 DOI: 10.1186/s12885-018-4748-0
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Gene Ontology Clusters of Differentially-Expressed Genes in all Primary and Metastatic NSCLC. a, b, Biological processes of overexpressed (a) and underexpressed genes (b) in Virus-infected NSCLC tumors, as compared to uninfected NSCLC tumors, were displayed. Black bars represent significantly overrepresented functions (FDR < 0.2). The number at the end of each bar indicates how many genes have the corresponding biological function. c, d, and e, Gene Set Enrichment Score were displayed for three significantly enriched oncogenic gene sets (FDR < 0.2). Positive enrichment score (ES) means that a majority of genes in those gene sets were concordantly overexpressed in Virus(+) NSCLC tumors
Overrepresented KEGG pathways of differentially expressed genes in virus-infected versus uninfected primary NSCLC specimens
| KEGG ID | Name | Count | Pop.Hits | Fold Enrichment | FDR | Genes | Total list | |
|---|---|---|---|---|---|---|---|---|
| Over-expressed genes in Virus-infected primary NSCLC tumors | hsa04110 | Cell cycle | 23 | 124 | 4.121 | 0.000 | E2F2, CDC6, FZR1, E2F4, RBL1, SKP2, PKMYT1, CHEK1, CDC20, PTTG1, MCM2, CDK4, CDC25B, MCM6, CCNE1, CDC45, CCNB2, CCND2, TFDP2, BUB1, BUB1B, CCNA2, STAG1 | 311 |
| hsa03050 | Proteasome | 10 | 44 | 5.050 | 0.001 | PSMF1, PSMC4, PSMC3, PSMD11, PSME2, PSMB3, PSMB2, PSMD2, PSMD3, PSME3 | 311 | |
| hsa04115 | p53 signaling pathway | 12 | 67 | 3.979 | 0.002 | CCNE1, CCNB2, CCND2, SERPINB5, RRM2, BAX, CHEK1, PMAIP1, PERP, CDK4, GTSE1, SESN3 | 311 | |
| hsa05203 | Viral carcinogenesis | 22 | 205 | 2.384 | 0.004 | HRAS, RBL1, UBR4, SKP2, ACTN1, CHEK1, CDC20, PMAIP1, MAPKAPK2, CDK4, SRF, PKM, CDC42, CCNE1, MAPK1, GTF2A1, CCND2, BAX, RANBP1, CCNA2, CHD4, DLG1 | 311 | |
| hsa04120 | Ubiquitin mediated proteolysis | 16 | 137 | 2.595 | 0.015 | FZR1, UBE2A, SOCS1, CBL, UBE4B, SKP2, UBE2J1, SAE1, CDC20, KEAP1, UBE2L3, BRCA1, FANCL, PIAS2, PIAS1, UBE2S | 311 | |
| hsa03015 | mRNA surveillance pathway | 12 | 91 | 2.930 | 0.030 | NXT1, NCBP2, SYMPK, FIP1L1, ALYREF, HBS1L, SRRM1, MSI2, SMG1, ETF1, PPP2R2B, PPP2R3C | 311 | |
| hsa05166 | HTLV-I infection | 23 | 256 | 1.996 | 0.031 | DVL3, E2F2, IL6, HRAS, TLN2, SLC25A5, ELK1, CHEK1, CDC20, PTTG1, CD40, MYBL2, CDK4, SRF, MSX2, POLE2, ELK4, CCND2, BAX, SLC2A1, BUB1B, RANBP1, DLG1 | 311 | |
| hsa03040 | Spliceosome | 13 | 133 | 2.172 | 0.187 | NCBP2, DHX8, SNRPA1, TRA2B, LSM6, U2SURP, ALYREF, SF3B3, CTNNBL1, SRSF4, TCERG1, SNRNP40, SNRPF | 311 | |
| Under-expressed genes in Virus-infected primary NSCLC tumors | hsa04024 | cAMP signaling pathway | 18 | 198 | 2.804 | 0.003 | ACOX1, ATP1B1, ROCK1, ROCK2, ADCY6, PDE4D, PDE4C, ATP1A2, PPP1CB, PLCE1, GRIA1, ABCC4, RAP1A, HHIP, HCN4, ADCY10, CACNA1D, HCAR1 | 224 |
| hsa04270 | Vascular smooth muscle contraction | 13 | 119 | 3.370 | 0.005 | ROCK1, PLA2G10, ROCK2, PPP1R12B, ADCY6, NPR2, ARHGEF12, PPP1CB, GNAQ, PLA2G12A, PLA2G12B, CACNA1D, PPP1R14A | 224 | |
| hsa01100 | Metabolic pathways | 59 | 1228 | 1.482 | 0.015 | ACOX2, ACOX1, CYP3A5, COX11, SGMS2, AMT, ALG2, ADH1A, PPOX, GPAT2, HIBADH, ASAH1, PDHB, ASAH2, ASPA, PIGM, NDUFS8, BPNT1, AGPAT2, NDUFS1, COX15, IDUA, NMNAT2, C1GALT1C1, HMGCLL1, SUCLG2, COX4I2, LPIN2, CDS1, TAT, ALDH3B1, ATP6V1C1, PLCE1, ALOX15B, MGAT5, AOC1, PRODH, ME3, LOC102724788, ALDOB, CTPS2, PLA2G12A, PLCH1, B3GNT6, PLA2G12B, BDH2, HSD17B7, ACSL5, PLA2G10, B3GALT2, KL, MAOA, NAT1, ACSM3, DBT, PON2, AHCYL2, ABO, PON3 | 224 | |
| hsa04390 | Hippo signaling pathway | 12 | 151 | 2.452 | 0.114 | BMP4, PARD6B, BMP2, TP53BP2, WTIP, FZD5, PPP1CB, BMP5, LLGL2, BMPR1A, CTNNB1, PPP2R2A | 224 | |
| hsa04972 | Pancreatic secretion | 9 | 93 | 2.985 | 0.121 | ATP1B1, SLC12A2, GNAQ, PLA2G10, PLA2G12A, PLA2G12B, ADCY6, RAP1A, ATP1A2 | 224 | |
| hsa00564 | Glycerophospholipid metabolism | 9 | 95 | 2.922 | 0.135 | GPD1L, LPGAT1, PLA2G10, PLA2G12A, PLA2G12B, LPIN2, GPAT2, CDS1, AGPAT2 | 224 | |
| hsa04961 | Endocrine and other factor-regulated calcium reabsorption | 6 | 45 | 4.113 | 0.168 | ATP1B1, GNAQ, KL, PTH1R, ADCY6, ATP1A2 | 224 | |
| hsa04510 | Focal adhesion | 14 | 206 | 2.096 | 0.182 | COL4A4, COL4A3, ROCK1, PAK3, ROCK2, FLT4, PPP1R12B, ITGA8, ITGA1, ITGA10, RAP1A, ACTN2, PPP1CB, CTNNB1 | 224 | |
| hsa04146 | Peroxisome | 8 | 83 | 2.973 | 0.199 | ACOX2, ACOX1, HMGCLL1, NUDT12, PEX1, ABCD3, PEX13, ACSL5 | 224 |
Count: the number of genes on the corresponding KEGG pathway among input DEGs;
Pop Hits: the number of genes on the corresponding KEGG pathway among all human genes
FDR: false discovery rate–adjusted p-value
Total list: the number of input DEGs
Fig. 2Viral carcinogenesis pathway and differentially expressed genes in primary NSCLC tumors. The viral carcinogenesis was displayed in part, focusing on three over-expressed genes in virus-infected Primary NSCLC tumors in comparison with uninfected primary tumors. Eclipse and rectangle boxes indicate viral product and host cellular target, respectively. a HPN (hepsin), b ACTN4 (actinin alpha 4), and c GP130 (interleukin 6 signal transducer) are host cellular targets of three different viral oncoproteins (HBx, Tax, and vIL-6) that lead to cell proliferation/survival, regulation of actin cytoskeleton, and proliferation angiogenesis, respectively
Differentially expressed genes in virus-infected versus uninfected primary NSCLC subtypes
| NSCLC Subtype | Virus (the number of tumors infected) | Gene Symbol | Average Expression when in Virus-uninfected | Average Expression in Virus-Infected | Fold Change | Up/Down in Virus-infected tumors | FDR q-value | Gene Description |
|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma ( | BLV ( | PSG4 | 58.325 | 6.142 | 0.105 | down | 0.033 | pregnancy specific beta-1-glycoprotein 4 |
| CPB2 | 124.383 | 8.635 | 0.069 | down | 0.156 | carboxypeptidase B2 | ||
| PlpPV.1 ( | GCM1 | 7.393 | 39.660 | 5.365 | up | 0.067 | glial cells missing homolog 1 | |
| SMR3A | 9.305 | 86.279 | 9.273 | up | 0.099 | submaxillary gland androgen regulated protein 3A | ||
| STLV.1 ( | MYEOV | 8.732 | 60.041 | 6.876 | up | 0.048 | myeloma overexpressed | |
| SPRR3 | 3205.815 | 15.053 | 0.005 | down | 0.048 | small proline rich protein 3 | ||
| FMN2 | 13.410 | 503.286 | 37.532 | up | 0.056 | formin 2 | ||
| GATA4 | 8.371 | 44.251 | 5.287 | up | 0.074 | GATA binding protein 4 | ||
| LOC105375229 | 8.548 | 87.248 | 10.207 | up | 0.120 | uncharacterized LOC105375229 | ||
| SEMA5B | 70.639 | 302.948 | 4.289 | up | 0.120 | semaphorin 5B | ||
| CNTNAP4 | 7.677 | 44.480 | 5.794 | up | 0.197 | contactin associated protein like 4 | ||
| STLV.2 ( | CRISP2 | 7.371 | 91.073 | 12.355 | up | 0.015 | cysteine rich secretory protein 2 | |
| Adenocarcinoma ( | Any ( | ACTC1 | 31.21 | 6.37 | 0.20 | down | 0.187 | actin, alpha, cardiac muscle 1 |
| PCSK2 | 260.71 | 19.03 | 0.07 | down | 0.144 | proprotein convertase subtilisin/kexin type 2 | ||
| HBV ( | CEACAM8 | 6.00 | 226.44 | 37.74 | up | 0.000 | carcinoembryonic antigen related cell adhesion molecule 8 | |
| PRSS1 | 9.37 | 238.98 | 25.49 | up | 0.035 | protease, serine 1 | ||
| CALB2 | 12.70 | 244.70 | 19.27 | up | 0.056 | calbindin 2 | ||
| NUDT4 | 6.41 | 25.36 | 3.96 | up | 0.109 | nudix hydrolase 4 | ||
| NAP1L6 | 5.57 | 19.92 | 3.57 | up | 0.071 | nucleosome assembly protein 1 like 6 | ||
| CEP170B | 192.56 | 68.38 | 0.36 | down | 0.083 | centrosomal protein 170B | ||
| MTND6P4 | 5241.96 | 1570.27 | 0.30 | down | 0.109 | mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 pseudogene 4 | ||
| NUP62 | 1710.30 | 406.58 | 0.24 | down | 0.012 | nucleoporin 62 kDa | ||
| Y73SV ( | MARCH3 | 14.08 | 36.38 | 2.58 | up | 0.151 | membrane associated ring-CH-type finger 3 | |
| ANKRD29 | 32.33 | 9.34 | 0.29 | down | 0.151 | ankyrin repeat domain 29 | ||
| NMNAT2 | 70.41 | 11.09 | 0.16 | down | 0.151 | nicotinamide nucleotide adenylyltransferase 2 | ||
| QSER1 | 386.06 | 47.97 | 0.12 | down | 0.151 | glutamine and serine rich 1 |
Fig. 3Gene Sets Enriched Significantly in Primary Squamous Cell Carcinoma. GSEA was performed on hall mark, oncogenic, and immunologic gene sets for individual viral type detected in primary squamous cell carcinoma. A positive GSEA score indicates that a majority of genes in the corresponding gene set are concordantly overexpressed in virus-infected SCC specimens and vice versa. Black bars represent significantly enriched gene sets (FDR < 0.2). a hallmark gene sets compared between BLV(+) and BLV(-) primary SCC b oncogenetic gene sets compared between BLV(+) and BLV (-) primary SCC, c hallmark gene sets compared between HPV(+) and HPV(-) primary SCC; d hallmark gene sets compared between STLV(+) and STLV(-) primary SCC
Fig. 4Virus-host protein-protein Interaction of differentially-expressed genes in virus-infected metastatic lung tumors. VirusMentha interactome analysis results are depicted for a nine overexpressed genes and b five under-expressed genes in Y73SV(+), as compared to Y73SV(-) metastatic lung tumor specimens. Viral proteins and their interaction target genes in host cells are colored cyan and indigo, respectively